Owkin

AI biotechnology company using federated learning and multimodal data for discovery and diagnostics.

Owkin applies machine learning to multimodal patient data — including histopathology, genomics, and clinical records — to identify drug targets, discover biomarkers, and develop diagnostics. Its federated learning approach lets models train across hospital datasets without moving the underlying patient data, and it partners with pharmaceutical companies on target discovery and clinical development.

Headquarters: Paris, France
Founded: 2016
Compliance: ISO 27001, GDPR
Deployment options: cloud, private-cloud
Website: https://www.owkin.com
LinkedIn: https://www.linkedin.com/company/owkin

AI Use Cases

Patient Recruitment & Enrollment
Target Identification & Validation

Vendor Scorecard

93% — Complete coverage. Coverage score — how completely Atlas documents Owkin across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.

Compliance & Validation — Documented

ISO 27001, GDPR

Deployment & Hosting — Documented

cloud, private cloud

Pricing Transparency — Documented

Partnership / milestone based

Implementation & Onboarding — Documented

6–12 months

Organization & Role Fit — Documented

Biotech Startup, Mid-Size Biotech, Large Pharma, Drug Discovery, R&D Leadership, Medical Affairs

Solution Scope — Documented

Biomarker Discovery, Real-World Evidence, Target Identification

Company Viability — Partially documented

Private, Founded 2016

Always ask the vendor

Not captured in Atlas data — confirm directly. Excluded from the score above.

Data Rights & IP

Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?

Model Credibility & Explainability

Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?

Clinical Trial Activity

1 registered trial where Owkin is the lead sponsor (1 currently recruiting). Source: ClinicalTrials.gov, verified 2026-07-29.

Top conditions studied: Diffuse Large B Cell Lymphoma, Solid Tumor Cancer

A Non-interventional, International, Multicentre Clinical Research Study to Build the Largest Collection of Multimodal Data (Including Clinical Data, Imaging Data and Omics Data) in Oncology (NCT06625203, recruiting)

Evidence & Outcomes

Bristol Myers Squibb multi-year clinical data science collaboration

Owkin entered a multi-year strategic collaboration with Bristol Myers Squibb to apply its AI capabilities to the design of clinical trials, initially focused on cardiovascular disease with potential to extend into other therapeutic areas.

press release (Owkin) · 2022-06-07 — Partner: Bristol Myers Squibb

Sanofi collaboration expanded to apply AI for drug positioning in immunology

Owkin expanded its collaboration with Sanofi into immunology, using its AI target-discovery engine to identify candidate gene targets and associated patient subpopulations to support tailored treatment design.

press release (Owkin) · 2024-03-21 — Partner: Sanofi

Questions to Ask This Vendor

How does federated learning preserve data privacy across sites?
What biomarker discoveries have you validated with partners?
Which therapeutic areas have the deepest data coverage?